Jay G Fuletra1, Andrew Watts2, Matthew G Kaag1, Erik Lehman3, Jay D Raman1, Suzanne B Merrill4. 1. Division of Urology, Department of Surgery, College of Medicine, The Pennsylvania State University, 500 University Drive, H055, Hershey, PA, 17033-0850, USA. 2. College of Medicine, The Pennsylvania State University, Hershey, PA, USA. 3. Department of Public Health Sciences, College of Medicine, The Pennsylvania State University, Hershey, PA, USA. 4. Division of Urology, Department of Surgery, College of Medicine, The Pennsylvania State University, 500 University Drive, H055, Hershey, PA, 17033-0850, USA. smerrill1@pennstatehealth.psu.edu.
Abstract
PURPOSE: Imaging characteristics in bladder cancer (BC), such as hydronephrosis, are predictive of ≥ pT3 disease at time of radical cystectomy (RC). The predictive capacity of other findings, such as perivesical stranding (PS), remains unclear. We investigated whether PS was associated with ≥ pT3 BC in patients who did not receive neoadjuvant chemotherapy (NAC). METHODS: We identified 433 patients with BC who underwent RC from 2003 to 2018 of which 128 did not receive NAC. Evidence of PS on pre-TURBT imaging was determined by radiologist review and a stranding grading system was created. Factors associated with PS and hydronephrosis were identified. Multivariable logistic regressions evaluated PS and hydronephrosis as predictors for ≥ pT3 BC. RESULTS: Of the 128 patients who did not receive NAC, 48 (38%) had pT3 and 12 (9%) had pT4 BC. 125 (98%) patients had CT and three (2%) had MRI. PS and hydronephrosis on imaging were identified in 19 (15%) and 45 (35%) patients. PS was not associated with imaging type (p = 0.38), BMI (p = 0.18), or pathologic T stage (p = 0.24). Hydronephrosis was more frequently associated with higher pathologic T stage (p = 0.034). Multivariable analysis demonstrated that PS was not predictive of ≥ pT3 BC (p = 0.457), while hydronephrosis was positively associated (p = 0.003). Stratification by grade of stranding did not improve the predictive capacity of PS (p = 0.667). CONCLUSION: While hydronephrosis is an indicator of higher stage BC, PS failed to be a reliable predictor of ≥ pT3 stage. These observations should give pause in using PS on imaging to guide decisions until further investigations can be explored.
PURPOSE: Imaging characteristics in bladder cancer (BC), such as hydronephrosis, are predictive of ≥ pT3 disease at time of radical cystectomy (RC). The predictive capacity of other findings, such as perivesical stranding (PS), remains unclear. We investigated whether PS was associated with ≥ pT3 BC in patients who did not receive neoadjuvant chemotherapy (NAC). METHODS: We identified 433 patients with BC who underwent RC from 2003 to 2018 of which 128 did not receive NAC. Evidence of PS on pre-TURBT imaging was determined by radiologist review and a stranding grading system was created. Factors associated with PS and hydronephrosis were identified. Multivariable logistic regressions evaluated PS and hydronephrosis as predictors for ≥ pT3 BC. RESULTS: Of the 128 patients who did not receive NAC, 48 (38%) had pT3 and 12 (9%) had pT4 BC. 125 (98%) patients had CT and three (2%) had MRI. PS and hydronephrosis on imaging were identified in 19 (15%) and 45 (35%) patients. PS was not associated with imaging type (p = 0.38), BMI (p = 0.18), or pathologic T stage (p = 0.24). Hydronephrosis was more frequently associated with higher pathologic T stage (p = 0.034). Multivariable analysis demonstrated that PS was not predictive of ≥ pT3 BC (p = 0.457), while hydronephrosis was positively associated (p = 0.003). Stratification by grade of stranding did not improve the predictive capacity of PS (p = 0.667). CONCLUSION: While hydronephrosis is an indicator of higher stage BC, PS failed to be a reliable predictor of ≥ pT3 stage. These observations should give pause in using PS on imaging to guide decisions until further investigations can be explored.
Authors: Martine Ploeg; Lambertus A L M Kiemeney; Geert A Smits; Henk Vergunst; Andre C Viddeleer; Arno D H Geboers; Hans van Berkel; Erika van Boven; Katja K H Aben; J Alfred Witjes Journal: Urol Oncol Date: 2010-05-06 Impact factor: 3.498
Authors: C J Stimson; Michael S Cookson; Daniel A Barocas; Peter E Clark; John E Humphrey; Sanjay G Patel; Joseph A Smith; Sam S Chang Journal: J Urol Date: 2010-03-17 Impact factor: 7.450
Authors: Phillip J Gray; Chun Chieh Lin; Ahmedin Jemal; William U Shipley; Stacey A Fedewa; Adam S Kibel; Jonathan E Rosenberg; Ashish M Kamat; Katherine S Virgo; Michael L Blute; Anthony L Zietman; Jason A Efstathiou Journal: Int J Radiat Oncol Biol Phys Date: 2014-04-01 Impact factor: 7.038
Authors: Georg C Bartsch; Rainer Kuefer; Juergen E Gschwend; Robert de Petriconi; Richard E Hautmann; Bjoern G Volkmer Journal: Eur Urol Date: 2006-07-28 Impact factor: 20.096
Authors: Sam S Chang; Bernard H Bochner; Roger Chou; Robert Dreicer; Ashish M Kamat; Seth P Lerner; Yair Lotan; Joshua J Meeks; Jeff M Michalski; Todd M Morgan; Diane Z Quale; Jonathan E Rosenberg; Anthony L Zietman; Jeffrey M Holzbeierlein Journal: J Urol Date: 2017-04-26 Impact factor: 7.450
Authors: J Alfred Witjes; Thierry Lebret; Eva M Compérat; Nigel C Cowan; Maria De Santis; Harman Maxim Bruins; Virginia Hernández; Estefania Linares Espinós; James Dunn; Mathieu Rouanne; Yann Neuzillet; Erik Veskimäe; Antoine G van der Heijden; Georgios Gakis; Maria J Ribal Journal: Eur Urol Date: 2016-06-30 Impact factor: 20.096
Authors: Jong Jin Oh; Seok-Soo Byun; Chang Wook Jeong; Cheol Kwak; Hyeon Hoe Kim; Ja Hyeon Ku Journal: Front Oncol Date: 2019-03-19 Impact factor: 6.244